09/22/2014

ApneaDx by iDAPT Somno

ApneaDx Debuts at MEDICA 2014

[ Canadian medical startup to introduce a game-changing, cordless medical device for accurate, comfortable and affordable sleep apnea diagnosis at home ]


TORONTO, September 22, 2014 – iDAPT Somno Inc. will showcase its initial disruptive product, ApneaDx, when making its first appearance at MEDICA 2014, the world’s largest annual medical trade fair, taking place this November 12-15 in Düsseldorf, Germany.


ApneaDx is a cordless disposable medical device for accurate, comfortable and affordable sleep apnea diagnosis. It represents a paradigm shift from existing technologies that use numerous wires to capture multiple channels of data. Instead, ApneaDx is intelligent technology that records and analyzes breath sound, an extremely “rich” data source, to generate multiple streams of information through its patented SoundTrac technology. One night of sleep in any position anywhere with this cordless, light weight and extremely easy-to-use face frame is all that is needed for an automatically generated and customizable diagnostic report. ApneaDx is clinically validated to be equivalent to the traditional gold-standard in-lab polysomnography for diagnosis of sleep apnea. As the only cordless diagnostic device for sleep apnea, ApneaDx offers accuracy and reliability in its minimalist form.


“Our primary goal at MEDICA2014 is to find worldwide distribution partnerships for ApneaDx to ensure its global success,” says Dr. Geoff Fernie, Chief Technology Officer at iDAPT Somno, “We are very excited to join many other Canadian innovative companies and be part of the Ontario, Canada Pavilion.”


About sleep apnea:


Sleep apnea, which is characterized by recurrent partial or complete pauses in breathing during sleep, is one of today’s biggest health concerns. Several studies around the world have shown that approximately 10% of the adult population has sleep apnea. If left untreated, sleep apnea could lead to a several-fold increase in the risk of hypertension, stroke, heart failure, and motor vehicle accidents. There is also emerging evidence demonstrating an association between sleep apnea and cancer mortality.


Currently, the gold-standard for diagnosing sleep apnea is polysomnography (PSG), a test performed in a sleep laboratory that measures the frequency of apneas and hypopneas per hour of sleep or apnea-hypopnea index (AHI). However, because PSG is expensive, inconvenient, time-consuming (6-8 hours in a sleep laboratory), uncomfortable (numerous electrodes and wiring are required), and has limited availability, the rate of sleep apnea diagnosis is very low. For example, in developed countries, the diagnosis rate is often less than 10%. We believe that ApneaDx provides a solution to this problem of under-diagnosis.


About iDAPT Somno:


Founded by the University Health Network and MaRS Innovation at Toronto, Ontario, Canada, iDAPT Somno Inc. is a Canadian start-up bringing together state-of-the-art technologies and innovations to provide effective solutions to many aspects of sleep disorders. Our innovations are driven by world-class scientists and engineers supported by an in-house business team.


To learn more about ApneaDx, please visit us during MEDICA 2014 at the Ontario/Canada Pavilion, Hall 16, Booth F44. You can also locate us in “Companies & Products” on the medica-tradefair.com portal.


Note: As of August 2014, ApneaDx is not yet licensed for sale.


For further information, please contact:


Gavin Ouyang, M.Biotech
Business Development and Operations
iDAPT Somno Inc.
550 University Avenue, Office 12-145
Toronto, Ontario M5G 2A2, Canada
+1 647-799-0639 ext. 616
ggouyang@idaptsomno.com
www.idaptsomno.com